A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy

E.J. Aspinall, W. Mitchell, J. Schofield, A. Cairns, S. Lamond, P. Bramley, S.E. Peters, H. Valerio, J. Tomnay, D.J. Goldberg, P.R. Mills, S.T. Barclay, A. Fraser, J.F. Dillon, N.K. Martin, M. Hickman, S.J. Hutchinson

Research output: Contribution to journalArticle

21 Downloads (Pure)

Abstract

Prisoners are a priority group for hepatitis C (HCV) treatment. Although treatment durations will become shorter using directly acting antivirals (DAAs), nearly half of prison sentences in Scotland are too short to allow completion of DAA therapy prior to release. The purpose of this study was to compare treatment outcomes between prison- and community-based patients and to examine the impact of prison release or transfer during therapy. A national database was used to compare treatment outcomes between prison treatment initiates and a matched community sample. Additional data were collected to investigate the impact of release or transfer on treatment outcomes. Treatment-naïve patients infected with genotype 1/2/3/4 and treated between 2009 and 2012 were eligible for inclusion. 291 prison initiates were matched with 1137 community initiates: SVRs were 61% (95% CI 55%–66%) and 63% (95% CI 60%–66%), respectively. Odds of achieving a SVR were not significantly associated with prisoner status (P=.33). SVRs were 74% (95% CI 65%–81%), 59% (95% CI 42%–75%) and 45% (95% CI 29%–62%) among those not released or transferred, transferred during treatment, or released during treatment, respectively. Odds of achieving a SVR were significantly associated with release (P<.01), but not transfer (P=.18). Prison-based HCV treatment achieves similar outcomes to community-based treatment, with those not released or transferred during treatment doing particularly well. Transfer or release during therapy should be avoided whenever possible, using anticipatory planning and medical holds where appropriate.
Original languageEnglish
Pages (from-to)1009–1016
Number of pages18
JournalJournal of Viral Hepatitis
Volume23
Issue number12
Early online date11 Aug 2016
DOIs
Publication statusPublished - Dec 2016

Fingerprint

Prisons
Hepatitis C
Therapeutics
Prisoners
Antiviral Agents
Scotland
Genotype
Databases

Keywords

  • hepatitis C
  • prison services
  • antiviral treatment

Cite this

Aspinall, E.J. ; Mitchell, W. ; Schofield, J. ; Cairns, A. ; Lamond, S. ; Bramley, P. ; Peters, S.E. ; Valerio, H. ; Tomnay, J. ; Goldberg, D.J. ; Mills, P.R. ; Barclay, S.T. ; Fraser, A. ; Dillon, J.F. ; Martin, N.K. ; Hickman, M. ; Hutchinson, S.J. / A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy. In: Journal of Viral Hepatitis. 2016 ; Vol. 23, No. 12. pp. 1009–1016.
@article{a1ec492f4b5d4a84bc2e02ab73e0f5d6,
title = "A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy",
abstract = "Prisoners are a priority group for hepatitis C (HCV) treatment. Although treatment durations will become shorter using directly acting antivirals (DAAs), nearly half of prison sentences in Scotland are too short to allow completion of DAA therapy prior to release. The purpose of this study was to compare treatment outcomes between prison- and community-based patients and to examine the impact of prison release or transfer during therapy. A national database was used to compare treatment outcomes between prison treatment initiates and a matched community sample. Additional data were collected to investigate the impact of release or transfer on treatment outcomes. Treatment-na{\"i}ve patients infected with genotype 1/2/3/4 and treated between 2009 and 2012 were eligible for inclusion. 291 prison initiates were matched with 1137 community initiates: SVRs were 61{\%} (95{\%} CI 55{\%}–66{\%}) and 63{\%} (95{\%} CI 60{\%}–66{\%}), respectively. Odds of achieving a SVR were not significantly associated with prisoner status (P=.33). SVRs were 74{\%} (95{\%} CI 65{\%}–81{\%}), 59{\%} (95{\%} CI 42{\%}–75{\%}) and 45{\%} (95{\%} CI 29{\%}–62{\%}) among those not released or transferred, transferred during treatment, or released during treatment, respectively. Odds of achieving a SVR were significantly associated with release (P<.01), but not transfer (P=.18). Prison-based HCV treatment achieves similar outcomes to community-based treatment, with those not released or transferred during treatment doing particularly well. Transfer or release during therapy should be avoided whenever possible, using anticipatory planning and medical holds where appropriate.",
keywords = "hepatitis C, prison services, antiviral treatment",
author = "E.J. Aspinall and W. Mitchell and J. Schofield and A. Cairns and S. Lamond and P. Bramley and S.E. Peters and H. Valerio and J. Tomnay and D.J. Goldberg and P.R. Mills and S.T. Barclay and A. Fraser and J.F. Dillon and N.K. Martin and M. Hickman and S.J. Hutchinson",
note = "Acceptance from journal webpage AAM: 12m embargo Deposit deadline not met - author provided exception reasons 12-12-16 (email in SAN) ^Exception status: author email in SAN; agreed no exception can be applied (library exception review, October 2018)",
year = "2016",
month = "12",
doi = "10.1111/jvh.12580",
language = "English",
volume = "23",
pages = "1009–1016",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "John Wiley & Sons",
number = "12",

}

Aspinall, EJ, Mitchell, W, Schofield, J, Cairns, A, Lamond, S, Bramley, P, Peters, SE, Valerio, H, Tomnay, J, Goldberg, DJ, Mills, PR, Barclay, ST, Fraser, A, Dillon, JF, Martin, NK, Hickman, M & Hutchinson, SJ 2016, 'A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy', Journal of Viral Hepatitis, vol. 23, no. 12, pp. 1009–1016. https://doi.org/10.1111/jvh.12580

A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy. / Aspinall, E.J.; Mitchell, W.; Schofield, J.; Cairns, A.; Lamond, S.; Bramley, P.; Peters, S.E.; Valerio, H.; Tomnay, J.; Goldberg, D.J.; Mills, P.R.; Barclay, S.T.; Fraser, A.; Dillon, J.F.; Martin, N.K.; Hickman, M.; Hutchinson, S.J.

In: Journal of Viral Hepatitis, Vol. 23, No. 12, 12.2016, p. 1009–1016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy

AU - Aspinall, E.J.

AU - Mitchell, W.

AU - Schofield, J.

AU - Cairns, A.

AU - Lamond, S.

AU - Bramley, P.

AU - Peters, S.E.

AU - Valerio, H.

AU - Tomnay, J.

AU - Goldberg, D.J.

AU - Mills, P.R.

AU - Barclay, S.T.

AU - Fraser, A.

AU - Dillon, J.F.

AU - Martin, N.K.

AU - Hickman, M.

AU - Hutchinson, S.J.

N1 - Acceptance from journal webpage AAM: 12m embargo Deposit deadline not met - author provided exception reasons 12-12-16 (email in SAN) ^Exception status: author email in SAN; agreed no exception can be applied (library exception review, October 2018)

PY - 2016/12

Y1 - 2016/12

N2 - Prisoners are a priority group for hepatitis C (HCV) treatment. Although treatment durations will become shorter using directly acting antivirals (DAAs), nearly half of prison sentences in Scotland are too short to allow completion of DAA therapy prior to release. The purpose of this study was to compare treatment outcomes between prison- and community-based patients and to examine the impact of prison release or transfer during therapy. A national database was used to compare treatment outcomes between prison treatment initiates and a matched community sample. Additional data were collected to investigate the impact of release or transfer on treatment outcomes. Treatment-naïve patients infected with genotype 1/2/3/4 and treated between 2009 and 2012 were eligible for inclusion. 291 prison initiates were matched with 1137 community initiates: SVRs were 61% (95% CI 55%–66%) and 63% (95% CI 60%–66%), respectively. Odds of achieving a SVR were not significantly associated with prisoner status (P=.33). SVRs were 74% (95% CI 65%–81%), 59% (95% CI 42%–75%) and 45% (95% CI 29%–62%) among those not released or transferred, transferred during treatment, or released during treatment, respectively. Odds of achieving a SVR were significantly associated with release (P<.01), but not transfer (P=.18). Prison-based HCV treatment achieves similar outcomes to community-based treatment, with those not released or transferred during treatment doing particularly well. Transfer or release during therapy should be avoided whenever possible, using anticipatory planning and medical holds where appropriate.

AB - Prisoners are a priority group for hepatitis C (HCV) treatment. Although treatment durations will become shorter using directly acting antivirals (DAAs), nearly half of prison sentences in Scotland are too short to allow completion of DAA therapy prior to release. The purpose of this study was to compare treatment outcomes between prison- and community-based patients and to examine the impact of prison release or transfer during therapy. A national database was used to compare treatment outcomes between prison treatment initiates and a matched community sample. Additional data were collected to investigate the impact of release or transfer on treatment outcomes. Treatment-naïve patients infected with genotype 1/2/3/4 and treated between 2009 and 2012 were eligible for inclusion. 291 prison initiates were matched with 1137 community initiates: SVRs were 61% (95% CI 55%–66%) and 63% (95% CI 60%–66%), respectively. Odds of achieving a SVR were not significantly associated with prisoner status (P=.33). SVRs were 74% (95% CI 65%–81%), 59% (95% CI 42%–75%) and 45% (95% CI 29%–62%) among those not released or transferred, transferred during treatment, or released during treatment, respectively. Odds of achieving a SVR were significantly associated with release (P<.01), but not transfer (P=.18). Prison-based HCV treatment achieves similar outcomes to community-based treatment, with those not released or transferred during treatment doing particularly well. Transfer or release during therapy should be avoided whenever possible, using anticipatory planning and medical holds where appropriate.

KW - hepatitis C

KW - prison services

KW - antiviral treatment

U2 - 10.1111/jvh.12580

DO - 10.1111/jvh.12580

M3 - Article

VL - 23

SP - 1009

EP - 1016

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

IS - 12

ER -